2011
DOI: 10.3892/ijo.2011.1061
|View full text |Cite
|
Sign up to set email alerts
|

18α-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes

Abstract: Abstract. Glycyrrhetinic acid is an active triterpenoid metabolite of glycyrrhizin abundantly present in licorice roots. Glycyrrhetinic acid exists as α and β stereo-isomeric forms. Both stereo-isomeric forms are known to have anti-inflammatory and anticancer activity. However, the effects and anticancer mechanism of α glycyrrhetinic acid in prostate cancer cells has not yet been evaluated. Therefore, we investigated the growth inhibition, induction of apoptosis and the anticancer mechanisms of 18α-glycyrrheti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
25
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 48 publications
(26 citation statements)
references
References 46 publications
1
25
0
Order By: Relevance
“…Studies comparing anti-cancer effects of Glycyrrhizin and its aglycon, Glycyrrhetinic acid (GA), in proliferation assays with murine melanoma cell line, found GA to be substantially more potent than its origin substance [23]. GA also presented anti-proliferative effects in leukemia [24] and human ovarian cancer cell lines [25], and was shown to target prostate cancer cells via an anti-inflammatory pathway through downregulation of HMGB1, IL-6 and IL-8 [26]. However, the compound has poor water solubility [27], thus presenting a pharmacological disadvantage.…”
Section: Discussionmentioning
confidence: 99%
“…Studies comparing anti-cancer effects of Glycyrrhizin and its aglycon, Glycyrrhetinic acid (GA), in proliferation assays with murine melanoma cell line, found GA to be substantially more potent than its origin substance [23]. GA also presented anti-proliferative effects in leukemia [24] and human ovarian cancer cell lines [25], and was shown to target prostate cancer cells via an anti-inflammatory pathway through downregulation of HMGB1, IL-6 and IL-8 [26]. However, the compound has poor water solubility [27], thus presenting a pharmacological disadvantage.…”
Section: Discussionmentioning
confidence: 99%
“…HMGB1 is highly expressed in PCa cells92 and targeting HMGB1 disrupts tumor progression by inhibiting activation of T-cells and reducing infiltration of macrophages which are considered to be key inflammatory cells in promoting variety of cancers including PCa 93. Interestingly, androgen deprivation caused HMG1's secretion in prostatic stromal cells supporting the notion that deprivation therapy may upregulate the expression of HMGB1 leading to either hormone resistance or metastatic disease 94…”
Section: Inflammationmentioning
confidence: 95%
“…While surgery, androgen ablation and radiation therapy are effective treatments of prostate cancer, cases commonly progress to a hormone independent state. The current standard of treatment in advanced, hormone-refractory prostate cancer is unsatisfactory [2]. New modalities of treatment are, therefore, needed.…”
Section: Introductionmentioning
confidence: 99%